Abstract
The emergence of West Nile virus (WNV) in North America in 1999 as a cause of severe neurological disease in humans, horses and birds stimulated development of vaccines for human and veterinary use, as well as polyclonal/monoclonal antibodies and other immunomodulating compounds for use as therapeutics. Although disease incidence in North America has declined since the peak epidemics in 2002-2003, the virus has continued to be annually transmitted in the Americas and to cause periodic epidemics in Europe and the Middle East. Continued transmission of the virus with human and animal disease suggests that vaccines and therapeutics for the prevention and treatment of WNV disease could be of great benefit. This article focuses on progress in development and evaluation of vaccines and immunotherapeutics for the prevention and treatment of WNV disease in humans and animals.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 269-285 |
| Number of pages | 17 |
| Journal | Immunotherapy |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2011 |
Keywords
- West Nile virus
- monoclonal antibodies
- passive immunization
- vaccine
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology